Clinical trial
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily
NCT00002241 · Merck Sharp & Dohme LLC, Industry · Unknown status
Key facts
| NCT number | NCT00002241 |
|---|---|
| Title | Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily |
| Official title | A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 100 Mg/d4T/3TC b.i.d. in HIV-Infected Individuals |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Indinavir sulfate, Ritonavir, Lamivudine, Stavudine |
| Enrollment | 80 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: